Sickle Cell Updates-Slides

Slides

Pdf Summary

This 2024 update on Sickle Cell Disease (SCD) by Dr. Leila M. Ndong from the University of Pennsylvania Health System provides a comprehensive overview of SCD management, complications, and emerging therapies. SCD is the most common monogenic disease, predominantly affecting individuals of African descent due to the protective sickle cell trait against malaria. Despite optimal treatment, patients’ life expectancy remains reduced by about 30 years compared to the general U.S. population.<br /><br />SCD’s hallmark complication is vaso-occlusive episodes (VOE), caused by rigid, sickled red blood cells that obstruct microcirculation, resulting in acute pain requiring prompt opioid management alongside hydration and supportive care. Guidelines from NHLBI (2014) and the American Society of Hematology (ASH, 2020) emphasize individualized care plans, combining opioids with NSAIDs when appropriate, and non-pharmacologic strategies. Patient-controlled analgesia is linked to quicker pain relief and reduced hospital length of stay. Chronic pain affects over half of adults with SCD and may require multimodal management including antidepressants, anticonvulsants, behavioral therapies, with cautious opioid use only if other measures fail.<br /><br />Acute chest syndrome, a severe lung complication, demands rapid oxygenation, broad antibiotic therapy, and transfusion to prevent respiratory failure. Delayed hyper-hemolytic transfusion reactions are serious risks after transfusions. Preoperative transfusion to a hemoglobin target of about 10 g/dL reduces surgical complications in procedures like cholecystectomy.<br /><br />Treatment innovations include FDA-approved gene therapies targeting BCL11A (2023) that increase fetal hemoglobin and reduce sickling, alongside established options like hydroxyurea, L-glutamine, crizanlizumab, and voxelotor. Hematopoietic stem cell transplantation offers a curative option but is limited by donor availability and risks.<br /><br />The presentation highlights pervasive racial disparities and negative perceptions of SCD patients, urging systemic actions to combat structural and interpersonal racism in care. Recommendations include universal social determinant screening, SCD-centered care centers, bias training, patient empowerment, and respectful language to improve outcomes and equity for this complex, lifelong disease.

Keywords

Sickle Cell Disease

SCD management

vaso-occlusive episodes

acute chest syndrome

opioid pain management

gene therapy BCL11A

hydroxyurea

hematopoietic stem cell transplantation

racial disparities in healthcare

social determinants of health